Press Releases

Investor Alerts

Jun 11, 2020

Satsuma Pharmaceuticals to Present Two Posters at the American Headache Society’s Annual Scientific Meeting hosted via a Virtual Meeting Platform

Meeting Launch date is Saturday, June 13th 2020 at 9:00am (PT)
Jun 1, 2020

Satsuma Completes Enrollment in Pivotal Phase 3 EMERGE trial of STS101 for Acute Treatment of Migraine

More than 1,140 patients randomized and topline results expected in second half 2020
May 27, 2020

Satsuma Pharmaceuticals to To Present at the Jefferies Virtual Healthcare Conference
May 18, 2020

Satsuma Pharmaceuticals Announces Poster Presentations on the American Academy of Neurology 2020 Science Highlights Virtual Platform

Pharmacokinetic comparison of STS101, an intranasal dry powder formulation of dihydroergotamine, with other intranasal, injectable and oral inhaled DHE formulations
May 12, 2020

Satsuma Pharmaceuticals Reports First Quarter 2020 Financial and Business Results

STS101 EMERGE™ Phase 3 efficacy trial remains on track with announcement of topline data expected in second half of 2020

Show per page